News Roundup | Merck Challenges Safety & Validity Of Ivermectin Studies

Merck Challenges Safety & Validity of All Ivermectin Studies for COVID-19, Despite Having Donated Billions of Doses to Less-Developed World to Fight Parasites & Accumulating Positive Data:

A February 4 press release from Merck is raising yet more questions about why research money is not going to ivermectin and why this seemingly effective drug is so underutilized, even in North American research. In the statement Merck, one of America’s great pharmaceutical companies and manufacturer of the Stromectol/Mectizan branded versions of ivermectin, claims that: 1) there is no evidence that ivermectin works for COVID-19, and 2) there is a “concerning lack of safety data in the majority of studies,” suggesting that the drug may be unsafe.

WHO’s Dr. Maria Van Kerkhove: Ivermectin ‘Has Shown Promising Results in Some Trials’:

The World Health Organization (WHO) held a media briefing including Dr. Maria Van Kerkhove and Dr. Soumya Swaminathan to discuss the potential of ivermectin as a generic drug, demonstrating some promise as a treatment for at least mild, early-onset COVID-19. Dr. Van Kerkhove, a technical lead of this global organization’s COVID-19 response and expert in emerg...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee